Ventrus Biosciences Announces Results From Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure

[GlobeNewswire] – NEW YORK — Ventrus Biosciences, Inc. today announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related … more

View todays social media effects on VTUS

View the latest stocks trending across Twitter. Click to view dashboard

See who Ventrus is hiring next, click here to view